Metmin 500mg

Tablet
Metformin Hydrochloride
Alco Pharma

Other Strength:
- Metmin 850mg

Alternative:
- Informet 500mg
- Nobesit 500mg
- Comet XR 500mg
- Glymin 500mg
- Glymin® XR 500mg
- Metarin 500mg
- Metform 500mg
- Metform ER 500mg
- Verimet 500mg
- Meglu 500mg
- Meglu ER 500mg
- Glucomet 500mg
- Glucomet XR 500mg
- Metfomin 500mg
- Benformin 500mg
- Comet 500mg
- Daomin 500mg
- Daomin XR 500mg
- Bigmet XR 500mg



Metmin
Description:
Metmin is a preparation of Metformin Hydrochloride. It is a biguanide type oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin acts by decreasing intestinal absorption of glucose, reducing hepatic glucose production, and improves insulin sensitivity thus enhancing peripheral glucose uptake and utilization of glucose.

Composition:
Metmin 500: Each film coated tablet contains Metformin Hydrochloride BP 500 mg.
Metmin 850: Each film coated tablet contains Metformin Hydrochloride BP 850 mg.

Indication/Use:
Metmin as monotherapy is indicated as an adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be satisfactorily managed on diet alone. Metmin is also indicated for use concomitantly with a sulfonylurea when diet and Metformin Hydrochloride or sulfonylureas alone do not result in adequate glycemic control.

Dosage Guideline:
Adults:
Metmin500 mg & 850mg:The usual starting dose of Metformin is 500 mg twice a day or850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For those patients requiring additional glycemic control, Metmin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals.

Concomitant Metmin and oral sulfonylurea therapy in adult patients:

If patients have not responded to four weeks of the maximum dose of Metminmonotherapy, consideration should be given to gradual addition of an oral sulfonylurea.

Concomitant Metmin and Insulin Therapy in Adult Patients:

The current insulin dose should be continued upon initiation of Metmin therapy. Metmin therapy should be initiated at 500 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of Metmin should be increased by 500 mg after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control is achieved. The maximum recommended daily dose is 2500 mg for Metmin.

Children:
The usual starting dose of Metmin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses.

Geriatric Use:
Metmin should only be used in patients with normal renal function. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function.

Side Effects:
The most common side effect of Metformin is diarrhoea, nausea, vomiting, abdominal bloating, flatulence, and anorexia. Lactic acidosis also rarely occurs. Long- term use of Metformin has been associated with malabsorption of vitamin B12.

Contraindication:
Metformin is contraindicated in patients with hypersensitivity to Metformin or to any of its ingredients. It is also contraindicated in renal disease or dysfunction, congestive heart failure, acute myocardial infarction and diabetic ketoacidosis.

Drug Interaction:
Plasma concentration of Metformin is increased if Metformin co-administrates with furosemide, nifedipine, amiloride, digoxin, ranitidine, triamterene, and trimethoprim. Thus, careful patient monitoring and dose adjustment of Metformin and/or the interfering drug is recommended in patients who are taking such drugs. When such drugs are administered to a patient receiving Metformin, the patient should be closely observed to maintain adequate glycemic control.

Use in Pregnancy & Lactation:
Safety of Metmin in pregnant woman has not been established. Metmin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Metmin is secreted in human milk. Because many drugs are excreted in human milk, it should not be administered to a breast-feeding woman.

Over Dose:
Hypoglycemia has not been seen even with ingestion of up to 85 grams of Metformin, although lactic acidosis has occurred in such circumstances. Hemodialysis may be useful for removal of accumulated drug from patients in whom Metformin over dosage is suspected.

Precaution:
Metformin Hydrochloride therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. It should be used with caution in case of excessive alcohol intake and hepatic insufficiency. Metformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. It should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.

Therapeutic Class:
Antidiabetic

Dosage Form:
Tablet

Storage:
Store in a cool and dry place, protected from light.





এই পাতাটি ১৫১ বার দেখা হয়েছে